Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):150-9. doi: 10.1177/1074248410387606. Epub 2010 Dec 15.

Aldosterone antagonists in heart failure.

Author information

  • 1University of South Florida, Tampa, FL 33647, USA. mguglin@gmail.com

Abstract

Aldosterone antagonists represented by nonselective spironolactone and mineralocorticoid-selective eplerenone are approved for treatment of symptomatic heart failure with reduced systolic function. Their cardioprotective, antifibrotic, and antiarrhythmic effects have been proven in animal experiments, and their effects on morbidity and mortality have been demonstrated in randomized clinical trials. Yet, they remain the most underutilized of all classes of medications for heart failure, primarily because of fear of hyperkalemia. Thorough patient screening and selection is the key for minimizing risks and optimizing benefits from these drugs. Ongoing trials will demonstrate whether the indication for aldosterone antagonists can be expanded to less severe heart failure or patients with preserved systolic function.

PMID:
21160084
DOI:
10.1177/1074248410387606
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center